0.00Open0.65Pre Close0 Volume75 Open Interest2.50Strike Price0.00Turnover107.73%IV10.63%PremiumAug 16, 2024Expiry Date0.43Intrinsic Value100Multiplier24DDays to Expiry0.22Extrinsic Value100Contract SizeAmericanOptions Type-0.7077Delta0.6045Gamma3.94Leverage Ratio-0.0038Theta-0.0011Rho-2.79Eff Leverage0.0018Vega
Immutep Stock Discussion
Immutep Announces Successful Meeting With FDA On Phase III Design In Non-Small Cell Lung Cancer; TACTI-004 Registrational Trial Will Enrol ~750 Patients Regardless Of PD-L1 Expression In Order To Address The Entire 1l NSCLC Market Eligible For Anti-PD-1 Therapy
Final discussion with the FDA, successfully concluding the regulatory preparations for the TACTI-004 Phase III trial design to evaluate efti in combination with KEYTRUDA (pembrolizumab), MSD's anti-PD-1 therapy, and sta...
Benzinga· 5 mins ago
LAG-3 Agonist Antibody Designed to Treat Autoimmune Diseases
• Study expected to enrol first participants during Q3 CY2024
SYDNEY, AUSTRALIA – 17 July 2024 – Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces it has received regulatory clearanc...
No comment yet